

Hyloris is first Belgian-headquartered Company to adopt Euronext Securities' new European CSD model

Strengthened model to enhance Shareholder intelligence, Investor visibility and Capital
Markets positioning - Seamless transition for shareholders

Liège, Belgium - 14 October 2026 – 16:00 CEST – Non-Regulated Information - Hyloris Pharmaceuticals SA (“Hyloris”) (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announces that it has become the first company with headquarters in Belgium to join Euronext Securities under Euronext's new European Central Securities Depository (CSD) model. As from October 14, 2026, Hyloris' shares are held and settled through Euronext Securities, while they will continue to trade on Euronext Brussels under the same ticker (XBR: HYL) and ISIN code.

Euronext's new European CSD model gives issuers a genuine choice of CSD and broader access to European investors. As an early adopter, Hyloris establishes an active, long-term collaboration with Euronext Securities, with tangible benefits for the Company and its stakeholders resulting in active and cost-efficient partnership by obtaining a dedicated, competitive issuer service, going beyond a purely administrative relationship:

- **Enhanced visibility and investor access:** greater exposure to European investors, facilitating connectivity between financial intermediaries across European markets and better means to engage current and prospective shareholders, including through Euronext initiatives and events.
- **Deeper Shareholder intelligence:** more complete and frequent quantitative and qualitative Hyloris' shareholders identification, enabling more targeted investor relations and consolidation of operational complexity.
- **Support for the long-term strategy:** building a stable, well-informed and engaged shareholder base aligned with Hyloris' long-term value creation.

Smooth transition for shareholders

Hyloris, Euronext Securities and the intermediaries involved worked closely together to ensure a smooth transition. The migration does not affect shareholders' economic or voting rights, and shareholders continue to hold and trade Hyloris shares through their existing financial intermediaries. Shareholders do not need to take any action and accounts are unchanged: holdings are transitioned automatically, trading on Euronext Brussels continues under the same ticker and ISIN code, and registered shareholders remain recorded in Hyloris' share register. Questions can be addressed to shareholders' bank or to investorrelations@hyloris.com.

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: *“We are proud to be the first company that moved to Euronext Securities' new European CSD model. This partnership supports our long-term strategy, giving us better insight into our shareholders, more ways to engage with them and greater visibility among European investors. As an innovative international, European, Belgian headquartered company, we are pleased to contribute to a more integrated European capital market.”*

Benoît van den Hove, CEO Euronext Brussels, said: *"We are proud to welcome Hyloris to Euronext Securities. As the leading European market infrastructure, Euronext is taking concrete and decisive steps to deliver a genuine Savings and Investments Union. A few days ago, we launched our new, innovative European CSD model. It introduces greater choice and consolidation in Europe's post-trade and offers clients a broadened access to European capital markets. The early adoption of this model by an innovative biotech such as Hyloris is the proof that it delivers value for ambitious European businesses."*

On 20 October 2026, Hyloris' CEO Stijn Van Rompay will ring the opening bell at Euronext Brussels to celebrate the migration, joined by Benoît van den Hove, CEO of Euronext Brussels and Pierre Davoust, CEO of Euronext Securities.

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio including more 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved and commercialized in the U.S.: Podofilox Gel and Tranexamic Acid RTU. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide.*** Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (XBR: HYL) with about 54 people across 13 nationalities, targeting time-to-market of 7 years at an average cost of EUR 7 million per product (non-inflation adjusted).

For more information, visit www.hyloris.com and follow-us on [LinkedIn](#).

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO

legal representative of Impact WITH Empathy BV

Ann.dejaeger@hyloris.com

32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO

legal representative of SVR Management BV

stijn.vanrompay@hyloris.com

32 (0)4 346 02 07

Christophe Maréchal, CFO

legal representative of CMM&C srl

Christophe.Marechal@hyloris.com

32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means "high yield, lower risk", which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are "forward-looking

statements." These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.